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Coxsackievirus B3 (CVB3) is an important human pathogen that causes substantial morbidity and mortality but, to date, no vaccine is
available. We have generated an RNA-based vaccine against CVB3 and have evaluated it in the murine model of infection. The vaccine was
designed to allow production of the viral polyprotein, which should be cleaved to generate most of the viral proteins in their mature form; but
infectious virus should not be produced. In vitro translation studies indicated that the mutant polyprotein was efficiently translated and was
processed as expected. The mutant RNAwas not amplified in transfected cells, and infectious particles were not produced. Furthermore, the
candidate RNA vaccine appeared safe in vivo, causing no detectable pathology following injection. Finally, despite failing to induce
detectable neutralizing antibodies, the candidate RNA vaccine conferred substantial protection against virus challenge, either with an
attenuated recombinant CVB3, or with the highly pathogenic wt virus.
D 2004 Elsevier Inc. All rights reserved.
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Coxsackieviruses belong to the Picornaviridae family
and to the Enterovirus genus, which they share with
polioviruses, echoviruses, and unclassified enteroviruses.
They are classified, by their pathogenicity in newborn
mice (Hyypia et al., 1993), into groups A and B which
comprise 24 and 6 serotypes, respectively. The group B
coxsackieviruses (CVBs) commonly infect humans, but the
majority of infections (approximately 90%) are sub-
clinical, or give rise to minor bflu-likeQ symptoms;
however, these viruses can cause serious, and sometimes
lethal, disease. CVBs are the most common infectious
cause of human subacute, acute, and chronic myocarditis0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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1994; Reyes and Lerner, 1985; Woodruff, 1980); they
are a frequent cause of meningoencephalitis, particularly in
neonatal life (Daley et al., 1998; Modlin, 1988); and they
can cause severe pancreatitis (Arnesjo et al., 1976; Imrie et
al., 1977; Lal et al., 1988; Parenti et al., 1996).
Furthermore, although pancreatic infection often is limited
to acinar tissue, CVB also has been implicated in type 1
diabetes mellitus (Clements et al., 1995; Ramsingh et al.,
1997), which has a prevalence of approximately 0.2% in
the USA (LaPorte et al., 1995). Despite the frequency of
CVB infections, and the high associated morbidity and
mortality, no vaccine against these viruses has yet been
developed. In this study, we report our first attempts to
develop an RNA-based vaccine against type 3 CVB
(CVB3), using a murine model of CVB3 infection that
faithfully recapitulates many of the aspects of human
infection and disease. Both of the known receptors for
CVB—the coxsackievirus adenovirus receptor [CAR;04) 196–208YVIRO-02779; No. of pages: 13; 4C: 6
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decay accelerating factor [DAF (Bergelson et al., 1994,
1995; Shafren et al., 1995)]—are expressed in mice, and
CVB3 infection of this specie induces pancreatitis (Mena
et al., 2000; Ramsingh, 1997), meningitis (Gauntt et al.,
1984; Sethi and Lipton, 1981), myocarditis (Fujioka and
Kitaura, 2001; Kim et al., 2001), and myocardial scarring/
ventricular dilatation (Gebhard et al., 1998).
Although antibodies are usually considered the pre-
dominant factor in controlling enteroviral infections (Kew
et al., 1998; McKinney et al., 1987; Rudge et al., 1996; Yu
et al., 2000), CD8+ T cells also can play a part in limiting
CVB titers (Henke et al., 1995, 2003; Horwitz et al.,
2000). Therefore, a vaccine against CVB infection and
disease should induce both antibodies and T cells and, in
general, these two arms of the adaptive immune system
are best stimulated by proteins that are abundantly
synthesized within the host (Whitton and Oldstone,
2001). Other laboratories have designed vaccines against
coxsackievirus-induced diseases. Some protection was
conferred by several doses of an inactivated vaccine (See
and Tilles, 1994), which appears unlikely to have induced
strong T cell responses. Better protection was generated by
vaccines in which protein synthesis occurred within the
host cells, for example, live attenuated viruses (Fohlman et
al., 1993; Gauntt et al., 1983) and DNA vaccines (Henke
et al., 1998). However, these vaccines have some
disadvantages. Live attenuated viruses expose vaccinees
and their caregivers to the risk of revertant viruses which
may cause the very disease they are intended to prevent;
indeed, this is the major factor underlying the recent
preference, in developed countries, for killed (injected,
Salk) polio vaccine, over the live (oral, Sabin) vaccine.
DNA vaccines contain strong eukaryotic transcriptional
promoters, which if integrated into the host chromosome,
may activate a cellular gene, with potentially deleterious
consequences. Thus, we chose to evaluate RNA vaccines,
which—unlike DNA—cannot be integrated into the
genome; and which have been mutated to limit the
production of infectious materials (thereby reducing the
risk of reversion). RNA vaccines appear particularly
appropriate for picornaviruses, which have positive-sense
single-stranded RNA genomes; these molecules are infec-
tious following in vivo injection, allowing us to readily
construct a candidate vaccine.
The CVB3 genome is 7400 nucleotides (nt) in length
(Genbank U57056: ref Knowlton et al., 1996), and consists
of a 5Vuntranslated region (5VUTR) of 742 nt, followed by
one open reading frame of 6555 nt, that encodes the
approximately 220 kDa viral polyprotein which is co- or
post-translationally cleaved by virus-encoded proteases to
generate intermediate products that can have significant
half-lives, and may themselves have distinct functions. The
polyprotein is considered to have three general regions, P1–
P3. The P1 region, encoded near the N terminus of the
polyprotein, contains the four viral capsid proteins (1A, 1B,1C, and 1D, commonly known as VP4, VP2, VP3, and
VP1, respectively); the P2 region encodes three non-
structural proteins (2A–2C); and the P3 region yields four
mature non-structural polypeptides (3A–3D). Two of the
seven non-structural proteins are proteases (Kitamura et al.,
1981; Krausslich and Wimmer, 1988). In the present study,
we focused on the development of an RNA vaccine bearing
point mutations at the cleavage site between proteins 2A and
2B. Transfection of this RNA into cells—in tissue culture or
in vivo—was expected to produce CVB proteins and empty
capsids, but no infectious virus. Using this candidate RNA
vaccine, we addressed the following questions: (1) does the
mutant genome retain the capacity to act as a template for
viral polyprotein translation? (2) Do the mutations prevent
the production of infectious virus following RNA trans-
fections into tissue culture cells? (3) Is this candidate RNA
vaccine safe, as determined by the outcome of in vivo RNA
inoculation? (4) Can this RNA vaccine protect mice against
challenge with recombinant CVB3 (rCVB3) or with wild-
type CVB3 (wtCVB3)? (5) Are the protective benefits of
vaccination mediated by CVB-specific neutralizing anti-
bodies, as might be expected, given the natural history of the
virus?Results
Generation of a new plasmid pH3IH1 by site-specific PCR
mutagenesis
Complete processing of the coxsackievirus polyprotein
leads to the generation of 11 mature viral polypeptides. We
wished to derive a coxsackievirus B3 (CVB3) RNA vaccine
that: (i) would express a full-length mutant polyprotein,
thereby ensuring that most of the virus proteome would be
available for processing and presentation by the MHC class
I pathway; (ii) would undergo sufficient autolytic processing
to generate most of the mature virus proteins, including the
capsid proteins, thus maximizing the chance that any
antibodies induced would recognize the infectious virus;
(iii) would have a reduced capacity to shut down host
protein synthesis, increasing the chance that the transfected
cell could present virus epitopes via its antigen presentation
pathways; (iv) would not give rise to infectious particles,
diminishing the risk to the vaccinee. To this end, we targeted
the 3CDpro cleavage site [consensus sequence, AXXQˇG;
(Andino et al., 1994; Hanecak et al., 1982; Mattion et al.,
1994; Ypma-Wong et al., 1988)] at the junction between the
coxsackievirus 2A and 2B proteins. Few studies of
polyprotein processing have focused on coxsackieviruses,
and our selection of this target site was based on findings
with the closely related poliovirus. Mutations at the junction
between the polioviral 2A and 2B proteins have been
analyzed (Cohen et al., 1996), and the reported consequen-
ces appeared promising for our purposes: (i) lack of
cleavage at the 2A/B junction has no deleterious effects
I.P. Hunziker et al. / Virology 330 (2004) 196–208198on cleavage at other sites in the polyprotein; (ii) despite the
apparent normality of most processing, the mutant RNA
does not generate infectious particles; (iii) the 2A protein
has been implicated in the shut-off of host protein synthesis,
for both enteroviruses (Krausslich et al., 1987) and other
picornaviruses (Petersen et al., 1999), so preventing
maturation of 2A might permit better maintenance of host
cellular metabolism; (iv) mutation at the 2A/B junction
results in markedly reduced RNA replication (Cohen et al.,
1996) which may, in turn, diminish the risk that viral
revertants will emerge. Therefore, a plasmid (pH3IH1) was
constructed that contained point mutations at and near the
2A/B 3CDpro cleavage site, using as a template the plasmid
pH 3, which encodes a full-length infectious genome of
CVB3 (Knowlton et al., 1996). The cloning strategy is
outlined in diagrammatic form in Fig. 1. Mutations were
introduced by PCR-based site-directed mutagenesis. Two
pairs of PCR primers were synthesized: primers #1 and #3;
and primers #4 and #2. Primer #1 contained a BsaBI
restriction site (GATNN^NNATC), unique in the pH3
plasmid, and had the sequence 5VCCCTAGGAGATACCA-
ATCCCATGTGCTTTTAG3V [corresponding to nucleotides
(nt) 3565–3596 of the viral genome]. Primer #3
[5VCACTACCAGTTCCATTGCATCATCTTCCAGCCAC-
GTTCCATTGCATCATCTTCCAGCCACAGGAGATCA-
C3V] comprised complementary strand nucleotides 3751–Fig. 1. Construction of plasmid pH3IH1, encoding CVB3 with a mutated cleavage
with each viral protein represented by an arrow. The 5V untranslated region (5VUTR
to generate infectious RNA. Three unique restriction enzyme sites are included: Cl
and SpeI, involved in the site-directed mutagenesis (see text). The four primers use
black dots in primers #3 and #4, and the PCR cloning strategy is summarized. In t
that represent the wild-type 2A/2B junction are shown, along with the consensus c
the mutant plasmid pH3IHI is shown, with the three base changes in bold font, a
motif is absent from this sequence.3708, with two base changes (underlined). Primer #4
(nt 3708–3753; 5VGTGATCTCCTGTGGCTGGAAGATG-
ATGCAATGGAACTGGTAGTGAA3V) is complementary
to #3, and has complementary base changes (also under-
lined). Primer #2 (complementary strand nt 3850–3818;
5VTTGACCCACTAGTGATTCTTTCAGGAGGTTGAC3V)
contained an SpeI restriction site (A^CTAGT), unique in
pH3. For the initial PCR reactions, primer #1 was paired
with primer #3, while primer #4 was paired with primer
#2, and plasmid pH3 was used as template. The PCR
products were then eluted separately, combined, and used
as templates for the second-stage PCR, using primers #1
and #2. The resulting PCR product was digested with the
enzymes BsaBI and SpeI, then ligated into pH3 vector
which had been cleaved with the same enzymes. The
resulting plasmid pH3IH1 had the desired mutations [i.e.,
in position 3744 (AYT) which led to a replacement of
glutamine by leucine, and in position 3747 (GYT) which
replaced glycine with valine], and also a spontaneous
mutation occurring in position 3749 (GYA; valine to
methionine), which we accepted on the basis that it might
further diminish proteolytic cleavage at the 2A/B junction.
In addition, sequencing revealed a spontaneous mutation
in the cloned fragment (T3709YG; this mutation is silent
at the amino acid level, and so is not included in the
figure).site between the 2A and 2B proteins. The parental plasmid pH3 is shown,
) is shown as a rectangle, preceded by a T7 RNA polymerase promoter, used
aI (used to linearize the plasmid prior to in vitro RNA synthesis); and BsaBI
d for mutagenesis are indicated; the regions with altered bases are shown by
he lower part of the figure, the nucleotide and amino acid sequences of pH3
leavage site for the 3CDpro protease, AXXQˇG. The equivalent region from
nd the resulting three amino acid changes in bold italic font; the AXXQˇG
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mutant polyprotein is synthesized and that cleavage at the
2A/B site is interrupted
RNAs were transcribed in vitro using T7 RNA
polymerase, and were added to an in vitro translation
reaction. After a 4-h incubation, the labeled proteins were
analyzed by gel electrophoresis and autoradiography, and
the resulting data are shown in Fig. 2. The predicted
processing patterns of the wt and mutant P2 proteins are
shown in diagrammatic form. As indicated, the P2
protein normally is rapidly cleaved to generate 2A +
2BC; and the latter molecule subsequently is cleaved to
generate 2B + 2C. All four of these bands are present in
the pH3 lane (indicated by open dots). The mutant P2
protein, which lacks a cleavage site between 2A and 2B,
should generate only two bands: a novel 2AB band, and
the authentic 2C protein. Both are visible on the gel
(solid dots). Furthermore, in the absence of a 2A/B
cleavage site, one would predict that the 2BC, 2A, and
2B bands could not be generated; these bands are
missing from the pH3IH1 lane. Taken together, these
data indicate that pH3IH1 RNA is translated at high
efficiency, and that processing of the resulting polyprotein
occurs as expected.Fig. 2. In vitro translation of pH3 and pH3IH1 RNA. Cell free in vitro
translation was carried out as described in Materials and methods, using as
templates RNAs from pH3, or pH3IH1. As a negative control, no RNAwas
added to the reaction (left lane). The reaction mixtures were diluted in 2
lysis buffer, and 10 Al were run on a 12.5% polyacrylamide gel. The viral
bands of interest are indicated to the right of the autoradiograph. Processing
of normal P2, and predicted processing of mutant P2, are shown
diagrammatically, and the expected products are indicated on the radio-
graph (wt, o; mutant, !).pH3IH1 RNA fails to produce infectious progeny following
transfection of HeLa cells
Next, we determined if the RNA could give rise to
infectious virus. HeLa cells were transfected with 4 Ag of
either pH3IH1 RNA or pH3 RNA and, at 2, 4, 6, 8, 12, 18,
24, and 48 h post-transfection, supernatants were collected
and analyzed for viral titers in standard plaque assays. HeLa
cells were used in the RNA transfections because they
express the viral receptor hCAR (Tomko et al., 1997);
although this protein should not be required to permit
successful RNA transfection, we wished to maximize the
sensitivity of the assay by ensuring that any infectious virus
produced following RNA transfection could infect suscep-
tible cells, thus amplifying the sensitivity of the assay at
later time points post-transfection. For the wild-type pH3
RNA, a low titer of virus was present in the supernate as
early as 6 h after transfection and, by 18 h post-transfection,
titers had risen to a plateau level of approximately 8  107
pfu/ml (Fig. 3A). In contrast, and despite the inbuilt
amplification system which should permit the detection of
low levels of virus, no infectious progeny could be
identified, at any time point, in a standard plaque assay
using supernates from HeLa cells transfected with pH3IH1
RNA. Furthermore, no virus was detected when these
pH3IH1 supernates were incubated for a further 48 h with
uninfected HeLa cells (not shown). Thus, mutations at the
2A/B junction appear to very effectively prevent the
production of infectious CVB3, consistent with previous
findings using a 2A/B cleavage mutant of poliovirus (Cohen
et al., 1996).
Failure of 2A/B cleavage prevents RNA amplification in
transfected HeLa cells
To identify the stage(s) at which infectious virus
production might be blocked, we next determined if the
RNAs could replicate following transfection of tissue
culture cells. HeLa cells were transfected with 3 Ag of
either pH3IH1 RNA or pH3 RNA, and 0, 3, 6, 12, and 24
h later, RNA was harvested, immobilized on a slot–blot
apparatus, and incubated with radio-labeled strand-specific
RNA probes. The subsequent autoradiographs are shown
in Fig. 3B; the intensities of the bands were determined
using ImageJ software, and changes in genomic RNA
content over time also are shown. The intensities of the
bands representing genomic RNA (+ strand) in the
pH3IH1 and pH3 tracks were essentially identical at t =
0, indicative of equivalent amounts of input RNA.
However, the signal in pH3IH1-transfected cells decreased
thereafter, and was barely detectable at 24 h post-trans-
fection. In contrast, the genomic RNA signal in pH3-
transfected cells dropped marginally in the first 3 h, then
increased, at first gradually (6, 12 h) then dramatically (24
h). Anti-genomic ( strand) RNA also was readily
detected 24 h after pH3 RNA transfection, but was not
Fig. 3. Virus yield, RNA replication and protein synthesis following RNA transfection. Panel A: HeLa cells were transfected with either pH3 RNA or pH3IH1
RNA and, at the times indicated in the text, samples of supernatant were harvested and virus titers were determined. Panel B: RNA was harvested at various
times after transfection, and the contents of CVB + and  strand RNAwere determined by slot–blot analysis. The autoradiograph was scanned, and the band
intensities were determined using ImageJ software; the values are plotted (y axis shows arbitrary units). Panel C: As described in Materials and methods, HeLa
cells were infected with wtCVB3 or transfected with in vitro RNA transcripts from pH3 or pH3IH1, and a 35S metabolic label was added. The viral products
were immunoprecipitated with a polyvalent anti-CVB3 antibody, and were separated by electrophoresis through a 12.5% Tris-glycine polyacrylamide gel. The
sizes of marker proteins are shown (Kd), and the viral bands are identified, to the right of the autoradiograph. M = mock-transfected; V = virus-infected.
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the pH3IH1 RNA cannot be amplified following trans-
fection into HeLa cells.
pH3IH1 RNA transfection fails to generate abundant virus
protein
The production of viral proteins was evaluated by in
vitro radio-labeling, followed by immunoprecipitation, as
described in Materials and methods. The results are
shown in Fig. 3C, for: mock-transfected cells (lane M);
HeLa cells transfected with RNA derived from either the
pH3 plasmid, encoding wtCVB3, or from the mutated
pH3IH1 plasmid; and for virus-infected cells (lane V). Viral
proteins were present in proteins harvested from infected
cells, and from cells transfected with pH3, but proteins were
not detected in cells transfected with the pH3IH1 RNA.
Since the pH3IH1 RNA is an efficient template for protein
synthesis (Fig. 2), the absence of protein in transfected cells
is probably attributable to the lack of RNA amplification,leading to a dramatic difference in the quantity of template
available for translation, compared to cells transfected with
pH3 RNA.
pH3IH1 RNA is dramatically attenuated in vivo
From the viewpoint of vaccine safety, the demonstration
that pH3IH1 RNA could not be amplified in tissue culture,
nor produce virus, was encouraging. However, we felt it
important also to determine whether this mutant genome
was attenuated in vivo. As a positive control for infectivity
of viral RNA, 13 C57BL/6 mice were injected with pH3
RNA. Two of these mice died within days of injection, and
the others became ill, and were sacrificed on day 5, 7, or 9
post-injection. At each time point, the hearts and pancreata
of these mice had high titers of virus (not shown), and most
tissues showed marked pathological changes. A representa-
tive histological section of a pancreas harvested at 5 days
post-injection is shown (Fig. 4, left panel), and reveals
marked mononuclear cell infiltration, nuclear pyknosis, and
Fig. 4. RNA encoding wtCVB, but not the 2A/B mutant, results in pancreatitis. To determine the in vivo safety of the pH3IH1 candidate RNA vaccine, mice
were inoculated with the indicated RNAs as described in Materials and methods, and tissues were harvested at various times post-injection (see text). The
panels show trichrome-stained pancreatic sections (original magnifications 20) obtained at 5 days post-injection. The dotted circle encloses an area of focal
acinar cell destruction.
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circle); however, the islets of Langerhans were spared (as
previously reported for wtCVB infection: Mena et al.,
2000). The pathogenicity of pH3IH1 RNAwas evaluated in
a similar way, but using two strains of mice; normal C57BL/
6 mice, and B cell knockout mice, which were selected
because they are particularly susceptible to CVB3 infection
(Mena et al., 1999). pH3IH1 RNA was inoculated into 10
mice of each strain, and the mice were sacrificed 7 days
later. Virus was not detected in any of the tissues, and the
hearts and pancreata were histologically normal (Fig. 4,
right panel shows a representative pancreas). We conclude
that the abrogation of cleavage at the 2A/B junction yields
an RNA molecule which is non-pathogenic in vivo.
pH3IH1 RNA immunization confers significant protection
against rCVB3 challenge
Our failure to detect virus protein in pH3IH1-trans-
fected cells (Fig. 3) was disappointing, but the RNA is an
effective template for translation in vitro, and it is known
that only very small quantities of protein are required to
induce strong immune responses. This, together with the
demonstrated safety of the pH3IH1 construct, led us to
evaluate the protective efficacy of the pH3IH1 RNA in
vivo. Eight C57BL/6 mice were immunized with 15 Ag of
pH3IH1 RNA, three times at weekly intervals as described
in Materials and methods. We have previously shown that
nucleic acid vaccination can very rapidly induce protective
immunity (Zhang et al., 2002) so, 1 week after the third
immunization (4 weeks after the first), these mice, and a
control group of 8 non-immune mice, were challenged with
106 pfu of eGFP-CVB3, a recombinant CVB3 encoding
green fluorescent protein (Feuer et al., 2002). This virus is
attenuated in vivo, and doses as high as 107 pfu are non-lethal in adult mice, even if delivered intracranially (Feuer et
al., 2003). Three days later, the mice were euthanized, and
viral titers in the pancreata were determined. As shown in
Fig. 5A, high titers of virus (N108 pfu/g) were found in
seven of eight non-immunized mice, and the remaining
mouse had a titer of approximately 106 pfu/g. Four of the
mice in the immunized group also had high titers; but two
mice in this group had low titers (b105 pfu/g pancreas), and
virus was undetectable in the pancreata of the remaining two
individuals (indicated by asterisks). The difference between
the immunized and non-immunized groups is highly
statistically significant (P b 0.0041). Therefore, we con-
clude that the administration of pH3IH1 RNA can confer
measurable protection against infection by an attenuated
CVB3.
pH3IH1 immunization prolongs survival after wtCVB3
challenge
To test the protective efficacy of pH3IH1 RNA
vaccination against a more stringent challenge, 10
C57BL/6 mice were immunized as described above, and
were challenged with wtCVB3 (1.25  104 pfu, i.p.; N1
LD50). A group of 10 non-immune mice was used as a
control. Mice were observed daily for 1 month, and the
survival data are shown in Fig. 5B. Fifty percent of
immunized mice survived the challenge, compared with
only 20% of naive mice; this difference is not statistically
significant (P = 0.17). However, the vaccinees showed
substantially prolonged survival; when the two groups are
compared over the course of infection, the difference is
highly significant (P b 1.7  105). All of the surviving
mice displayed pathological changes in the pancreas,
indicative of their having been productively infected with
the wtCVB3.
Fig. 5. RNA vaccine protects against both rCVB3 and wtCVB3 challenges. Groups of C57BL/6 mice were immunized with pH3IH1 RNA, and subsequently
these groups, and control groups of age- and gender-matched non-immune C57BL/6 mice, were challenged with virus as described in Materials and methods.
Panel A: Mice (8 per group) were challenged with 106 pfu of an attenuated rCVB3 and, 3 days later, were euthanized, and the viral titers in their pancreata were
determined. Asterisks indicate samples in which no virus was present. The difference between the naRve and immunized groups is statistically significant
(Student’s t test, P b 0.0041). Panel B: Mice (10 per group) were challenged with 1.25  104 pfu (i.p.) of the highly pathogenic wtCVB3, and were observed
daily for morbidity and mortality. The number of mice surviving over a 28-day period is shown. The difference in the survival curves is highly significant
(Student’s t test, P b 1.7  105).
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Antibodies are known to play a key role in protecting
against picornavirus-induced diseases, and individuals with
defects in this arm of the immune system are at high risk of
acute or persistent enteroviral infection (Davis et al., 1977;
Geller and Condie, 1995; Hertel et al., 1989; Kew et al.,
1998). Therefore, we wished to evaluate the possible role of
neutralizing antibodies in the RNA vaccine-induced protec-
tive immunity shown in Fig. 5. One week after the third
RNA immunization (3 weeks after the first), immediately
prior to the viral challenges described above, blood samples
were collected, and sera were evaluated for the presence of
neutralizing antibodies, using a neutralization assay
described in Materials and methods. Positive control sera,
taken from a mouse that had recovered from wtCVB3
infection, contained a high level of neutralizing antibodies,
but none of the sera from RNA-immunized mice showed
any neutralizing activity (data not shown). Therefore, the
origin of the protective immunity conferred by RNA
immunization remains unclear, but may not depend on
neutralizing antibody activity. The identification of CVB-
specific CD8+ T cells is difficult because the native viral
epitopes are unknown. To circumvent this barrier, we
previously constructed recombinant CVB3 encoding well-
characterized epitopes from another virus, but we were
unable to detect strong induction of epitope-specific CD8+ T
cells by this recombinant CVB3 (Slifka et al., 2001).
Therefore, to attempt to evaluate virus-induced T cell
activity, we measured a surrogate marker; serum levels of
interferon-g (IFNg), an important antiviral cytokine that isproduced by CD8+ T cells. In all cases, IFNg levels were
below the level of detection in the sera of mice at 8 days
after challenge with wt CVB3 (data not shown).Discussion
Picornaviruses are important pathogens of humans (e.g.,
poliovirus, coxsackievirus) and ungulates (e.g., foot and
mouth disease virus), and enteroviruses are thought to cause
approximately 10–15 million symptomatic human infec-
tions annually in the USA (Sawyer, 2002). Most of these
infections are self-limiting, but in some cases they cause
substantial morbidity, and may even be lethal. Coxsack-
ieviruses can cause fatal myocarditis, hepatitis, and
meningo-encephalitis in adults (Bendig et al., 2001; Cree
et al., 2003; Kamei et al., 1990; Longson et al., 1969; Marks
et al., 1970), and are the leading infectious cause of
myocarditis in the USA. These viruses also are highly
pathogenic in neonates, who may succumb to myocarditis,
pancreatitis, choriomeningitis, and encephalitis (Chalhub et
al., 1977; Draganescu et al., 1980; Price et al., 1970).
Moreover, associations have been drawn between CVB and
sudden infant death syndrome (Cioc and Nuovo, 2002;
Dettmeyer et al., 2002). Despite the high prevalence, and
possible severe outcome, no vaccine is available to prevent
CVB infection or disease. Several candidate vaccines have
been designed, and tested in animal models. A polyvalent
inactivated vaccine conferred protection, when administered
in multiple doses (See and Tilles, 1994), and various live
attenuated viruses [e.g., temperature-sensitive mutants
(Gauntt et al., 1983), type-specific attenuated and chimeric
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Hofling et al., 2000; Zhang et al., 1997)] also have conferred
some degree of protection. As noted in the Introduction, live
attenuated viruses pose a real risk of reversion. The
attenuated viruses present in the Sabin vaccine rapidly
evolve in the vaccine recipient (Dunn et al., 1990), and may
infect caregivers or other contacts, causing the rare cases of
poliomyelitis that occur in developed countries (Evans et al.,
1985; Minor, 2003). Indeed, reversions of poliovirus
vaccine strains have led to several outbreaks, some of
which have been relatively localized (as in Haiti, in 2000:
Kew et al., 2002), although others have reached epidemic
proportions (as in Poland, in 1968: Martin et al., 2000). In
part to avoid this risk, DNAvaccines have been constructed,
and tested in animal models of coxsackieviral infection
(Henke et al., 1998, 2001; Toniolo et al., 2002). These
vaccines conferred some protection, but DNAvaccines carry
with them their own (presently theoretical) risk: the
possibility of harmful chromosomal integration. Depending
on their design, RNA vaccines may avoid the risks alluded
to above and, herein, we described the design, construction,
and evaluation of an RNA vaccine against CVB3.
We designed a vaccine in which polyprotein cleavage at
the 2A/B junction was interrupted. This strategy was chosen
for several reasons. We considered the P1 region to be
unsuitable for mutation because we wished all four mature
capsid proteins to be produced, potentially permitting the
induction of neutralizing antibodies; and we chose not to
alter the P3 region, which encodes the major viral protease,
as well as the viral replicase. We focused on the P2 region.
The 2A protein plays a key role in regulating translational
activity within the infected cells by redirecting the cellular
translational machinery from cap-dependent translation
[favoring host mRNAs] to IRES-dependent translation
[favoring viral mRNA] (Ziegler et al., 1995). Therefore,
limiting the activity of 2A (by preventing cleavage at the
2A/B junction) may maintain host cell translation, thereby
facilitating the processing and presentation of viral antigens;
however, this may be a double-edged sword, when viewed
from a vaccine perspective, because there may be a
corresponding reduction in IRES-driven translation, leading
to a lower quantity of available viral antigen. The 2B protein
also has been implicated in the shut-off of host protein
translation (van Kuppeveld et al., 1996b), although most
studies have indicated that—both for poliovirus and
coxsackievirus—the 2B protein, and/or its 2BC precursor
may be involved in viral replication (Cohen et al., 1996;
Johnson and Sarnow, 1991; van Kuppeveld et al., 1996a,
1997).
The molecular details of the mutations within the
candidate RNA vaccine are summarized in Fig. 1. Evalua-
tion of translation products of the mutant RNA in a cell-free
system indicated that the RNA acted as an efficient template
for translation, and that the mutant polyprotein was
processed exactly as predicted (Fig. 2); the 2A, 2B, and
2BC proteins—all of which rely on cleavage at the 2ABjunction—are absent, and a new 2AB protein appears.
Encouragingly, and in contrast to RNA representing the wt
virus sequence, the candidate RNA vaccine did not yield
infectious particles following transfection of susceptible
HeLa cells (Fig. 3A); and more importantly, the in vivo
inoculation of the pH3IH1 RNA failed to cause detectable
pancreatitis (Fig. 4) or myocarditis (not shown), and no
infectious virus was isolated from these tissues. This, again,
was in stark contrast to the outcome of inoculating wtRNA,
which almost invariably resulted in high viral titers, and
concomitant pancreatitis (Fig. 4). This failure to produce
infectious virus particles could have resulted from a defect
at various stages of the virus life-cycle (e.g., replication,
assembly, egress). We have shown that it is, most likely,
caused by a failure of RNA amplification (Fig. 3B).
Blockade at this very early stage of the life-cycle has both
advantages and disadvantages. On the one hand, in the
absence of RNA replication, there is a dramatically reduced
probability that variant viruses will emerge; thus, the
pH3IH1 vaccine is extremely safe. However, the reduced
quantities of intracellular RNA also will diminish the
available template for translation of the virus polyprotein,
as shown in Fig. 3C. Despite this concern, the RNA vaccine
described herein conferred significant protection against two
viral challenges. When vaccinated mice were challenged
with a high dose (106 pfu) of an attenuated virus, half of the
mice appeared able to more efficiently suppress virus
replication; however, the administration of the vaccine
was not invariably beneficial because the remaining 50%
of the mice showed virus titers similar to those observed in
the control group (Fig. 5A). A more rigorous challenge,
with N1 LD50 of wtCVB3, also provided strong evidence of
protection (Fig. 5B): even though the eventual mortality was
similar in both vaccinated and control groups, the former
showed significantly prolonged survival (P b 1.7  105).
What might explain the RNA vaccine-induced immun-
ity? Our understanding of the immune responses, which
control CVB infections, is limited. Antibodies seem to play
an important role in eradicating enteroviruses (Kew et al.,
1998; McKinney et al., 1987; Rudge et al., 1996; Yu et al.,
2000), and agammaglobulinemic humans are particularly
susceptible to chronic infections with coxsackieviruses
(Geller and Condie, 1995; Hertel et al., 1989; Palomba
and Tovo, 1999). Furthermore, the inactivated (Salk) polio
vaccine does not lead to protein synthesis within the cells of
the vaccine recipient, and so this vaccine is unlikely to
induce strong CD8+ T cell responses; as a result, its
protective efficacy has been attributed solely to the
induction of virus-specific antibodies. Therefore, we antici-
pated that CVB3-specific neutralizing antibodies would
underlie the protective effects of the RNA vaccine described
in the present study, and we were surprised by our inability
to detect any such antibodies in the sera of immunized mice
after three RNA immunizations. Although there is no doubt
that virus-specific neutralizing antibodies can protect against
enterovirus infection, a possible role for the T cell arm of the
I.P. Hunziker et al. / Virology 330 (2004) 196–208204adaptive immune response should not be overlooked. High
neutralizing antibody levels do not necessarily correlate
with low virus titers (Woodruff, 1979), and antibodies were
postulated to contribute little to the protection induced by a
CVB DNA vaccine (Henke et al., 1998), raising the
possibility that virus-specific CD8+ memory T cells might
play some part in vaccine-induced immunity against enter-
oviruses. Picornaviruses can induce CD8+ T cell responses
(Mandl et al., 1998) [although in general they appear to do
so rather poorly (Slifka et al., 2001)], and CD8+ T cells can
play a part in limiting CVB titers (Henke et al., 1995). CD8+
T cells may, in part, control CVB3 infections by their
production of IFNg, which diminishes CVB replication in
tissue culture and in vivo (Henke et al., 2003; Horwitz et al.,
2000); however, we were unable to detect this cytokine in
the sera of CVB3-infected mice. Adoptive transfer studies,
and analyses of transgenic knockout mice deficient in
various aspects of the immune response, are currently in
progress, and together should allow us to identify the
immunological component(s) responsible for protection.Materials and methods
Mice and tissue culture cells
Male C57BL/6 mice (H-2b MHC haplotype) and B cell
knockout mice (Kitamura et al., 1991) were obtained from
the Scripps Research Institute (TSRI) breeding facility, and
were between 8 and 16 weeks of age when experiments
were initiated. The HeLa cells used for virus titration and
growth, and for RNA transfections, were a kind gift from
Dr. Rainer Wessely (formerly at University of California,
San Diego) and were maintained in Dulbecco’s modified
Eagle medium (DMEM; GIBCO BRL, Invitrogen, Carls-
bad, CA) supplemented with 10% fetal bovine serum (FBS),
2 mM l-glutamine, 100 U/ml penicillin, and 100 Ag/ml
streptomycin (complete DMEM).
Viruses and plasmids
The coxsackievirus B3 used is a plaque-purified isolate
of the cardiopathogenic Woodruff strain of CVB3 (des-
ignated H3: Van Houten et al., 1991). An infectious clone of
this virus is available (Knowlton et al., 1996), and the
plasmid (pH3), generously provided by Dr. Kirk U.
Knowlton (University of California, San Diego), was used
as the parental plasmid for the construction of the candidate
RNA vaccine pH3IH1. The recombinant CVB3 encoding
enhanced green fluorescent protein (eGFP-CVB3), used as a
challenge virus in the present studies, was constructed in
this laboratory as previously described (Feuer et al., 2002).
Coxsackieviruses (wild-type and recombinant) were propa-
gated in HeLa cells (moi = 0.016). Sixteen hours post-
infection, the culture medium was removed, and the
monolayer of infected cells was frozen on dry ice. There-after, the cells were disrupted by three cycles of freezing and
thawing. Cell debris was removed by centrifugation, and
aliquots were stored at 70 8C. The titer of infectious virus
particles was determined by a standard plaque assay on
HeLa cell monolayers.
In vitro RNA transcription
The DNA template (pH3 or pH3IH1) was linearized with
the restriction enzyme ClaI (New England Bio Labs,
Beverly, MA), phenol-extracted, precipitated, and resus-
pended in sterile distilled water. One microgram of this
DNA was used as a template for transcription, using the
mMessage mMachine in vitro transcription kit (Ambion,
Austin, TX). Transcription was carried out according to the
manufacturer’s directions, then the template DNA was
removed by the addition of 1 Al of DNase, followed by
incubation at 37 8C for 15 min. RNA was recovered by
lithium chloride precipitation, as described in the instruction
manual.
In vitro translation
In vitro translation reactions were carried out as
described (Molla et al., 1991). Uncapped RNA was
produced using the MAXIscript kit (Ambion). For the
translation, 65% of S10 extract from HeLa cells, 1 bAll
fourQ buffer [10 buffer: 300 Al 1 M creatine phosphate,
300 Al 2 M KOAc, 100 Al creatine kinase (40 mg/ml in 10
mM HEPES–KOH, pH 7.4), 155 Al 1 M HEPES–KOH pH
7.4, 100 Al ATP, and 25 Al of each CTP, GTP, and UTP
(each from 0.1 M stock from Amersham Biosciences,
Piscataway, NJ)], 400 ng RNA, and 2 Al of 35S-methionine
(Amersham Biosciences) were mixed and used in 20 Al
reactions. The translation was performed at 30 8C for 4 h,
after which 2 lysis buffer was added, and the reactions
were heated to 90 8C for 5 min. Ten microliters of the
reactions were loaded and run on a 12.5% polyacrylamide
gel. The gel was dehydrated with three washes using
DMSO for 45 min each, and finally impregnated with 20%
PPO in DMSO for 1 h. Another wash in running H2O
followed for 1 h, before the gel was dried on a gel-dryer at
65 8C overnight and finally exposed to a photographic film
for 16 h.
Transfection of HeLa cells
To determine the infectious status of the RNA molecules,
and to evaluate viral protein production in tissue culture,
HeLa cells (at 70–80% confluency in a 6 well-plate) were
transfected with 3–6 Ag of the indicated RNA using
Lipofectin and OPTI-MEM (both GIBCO BRL, Invitrogen)
according to the manufacturer’s directions; in our hands,
25–50% of HeLa cells express the desired gene products
after transfection of nucleic acids. After 1 h, the transfection
mixture was aspirated, and replaced by complete media; this
I.P. Hunziker et al. / Virology 330 (2004) 196–208 205time point defined the beginning of the post-transfection
period.
Evaluation of CVB3 RNA replication by slot–blot
HeLa cells were transfected with RNA as described
above, and were harvested at 0, 3, 6, 12, and 24 h post-
transfection. RNA was extracted using TRIzol LS Reagent
(Invitrogen) according to the manufacturer’s directions.
RNA samples were dissolved in an aqueous solution
containing 50% formamide (J.T. Baker Inc., Phillipsburg,
NJ), 7% formaldehyde (Fisher Scientific, New Jersey, NJ),
and 1 SSC and incubated at 68 8C for 15 min. Then, two
volumes of 20 SSC (Ambion) were added, and each
RNA sample was loaded onto a nitrocellulose sheet in the
slot–blot manifold. After washing twice with 10 SSC,
the nitrocellulose was removed, baked for 2 h at 80 8C in a
vacuum oven, and crosslinked in a Stratalinker at 200
joules for 1 min. The nitrocellulose was pre-hybridized at
68 8C for 2 h in 50% formamide, 6 SSC, 5 Denhardt’s
reagent, 0.5% SDS (Ambion), and 100 Ag/ml boiled,
denatured salmon sperm DNA. Radiolabeled probes,
specific for either the genome or antigenome, were added
at 1  107 cpm/ml, and the blots were incubated at 68 8C
for approximately 20 h, after which the nitrocellulose was
washed three times: at RT using 1 SSC, 0.1% SDS; at 68
8C in 0.2 SSC, 0.1% SDS; and finally in 0.1 SSC,
0.1% SDS. The blot was exposed to Kodak film at 70 8C
with an intensifying screen. The intensities of the bands on
the resulting autoradiograph were quantified using the
public domain software ImageJ (available at NIH web site
http://rsb.info.nih.gov/ij/).
Evaluation of protein synthesis in transfected cells by 35S
metabolic labeling and immunoprecipitation
At 16 h post-transfection (or, as a positive control, at
16 h after infecting cells at a multiplicity of infection of
0.02), HeLa cells were washed with saline and starved for
30 min in methionine- and cysteine-free DMEM contain-
ing 10% FCS at 37 8C. 200 Al of 35S-labeled amino acids
(MP Biomedicals, Irvine, CA) were added (0.3 mCi/ml
final activity), and a 1-h incubation at 37 8C followed.
For subsequent immunoprecipitation, supernatants were
aspirated and discarded, and the cells were lysed in 1 ml
of RIPA lysis buffer (0.5% Nonidet P-40, 0.5 M EDTA, 5
M NaCl, 10% SDS, 1 M Tris [pH 8.0], 5 mM h-
mercaptoethanol in H2O). One microliter of a polyvalent
anti-CVB3 antibody was added to 500 Al of each lysate,
and the solutions were incubated, with gentle rotation, at
room temperature for 2 h. Thirty microliters of protein A
agarose beads (Sigma, St. Louis, MO) were added per
501 Al, and the samples were rotated for an additional
hour. The beads were washed five times with the RIPA
lysis buffer without h-mercaptoethanol, resuspended in 30
Al of 1 SDS buffer, frozen, then boiled for 5 min, andapplied to a 12.5% polyacrylamide gel, as described in
the text. The gel was dehydrated with three washes using
DMSO for 45 min each, and finally impregnated with
20% PPO in DMSO for 1 h. Another wash in running
H2O followed for 1 h, before the gel was dried on a gel-
dryer at 65 8C overnight and finally exposed to a
photographic film.
In vivo RNA inoculation
RNA was suspended in sterile PBS at a concentration of
300 Ag per ml, and 50 Al (15 Ag) were injected into the
tibialis anterior muscle. For studies of RNA infectivity,
samples were harvested at the indicated times post-injection.
For studies of RNA immunization, two boosts of RNAwere
administered as described above, at weekly intervals, and
the mice were challenged with virus 1 week later.
CVB3 infection of mice (virus challenge)
Mice were infected by intraperitoneal (i.p.) injection of
0.5 ml serum-free medium containing the stated amounts of
wtCVB3 or recombinant eGFP-CVB3, and were monitored
daily for morbidity and mortality, or were euthanized at the
indicated time points post-infection.
Organ preparation for titration and histology
The hearts and pancreata were removed from the mice
immediately after euthanasia. Each organ was divided into
two approximately equal portions, one of which was placed
into a cryotube and fast-frozen in dry ice for later virus
titration. The other portion of each organ was fixed in 10%
normal buffered formalin, and processed for histological
analyses. Five micron paraffin sections were prepared, and
were stained either with hematoxylin and eosin (H&E) or
with Masson’s trichrome.
Plaque assays (viral titration)
HeLa cells were plated in six well plates (5–7.5  105
cells/well) and incubated at 37 8C with 5% CO2 for
approximately 24 h, at which time they reached approx-
imately 70–90% confluency. The weight of each frozen
organ sample was determined, then the tissue was homo-
genized in 1 ml of DMEM, and 10-fold serial dilutions were
prepared in DMEM. Media was aspirated from the 6-well
plates, and 400 Al of each serial dilution was added to
individual wells. Plates were incubated at 37 8C for 1 h,
with gentle rocking every 15 min. Next, cells were overlaid
with 4 ml of 1 DMEM in 0.6% agar (1:1 mixture of 2
DMEM at 37 8C and 1.2% agar at 55 8C). At approximately
48 h post-infection, cells were fixed in methanol/acetic acid
(3:1 v/v), and agarose plugs were removed. The monolayers
were stained with 0.5% crystal violet in 20% ethanol, rinsed
in tap water, and plaques were counted. The titer (in pfu/g of
I.P. Hunziker et al. / Virology 330 (2004) 196–208206organ) was calculated based on the known weight of each
tissue sample.
Virus neutralization assay, and measurement of serum IFNc
Blood was collected from the tail and, after clotting, the
serum was recovered. Sera were incubated at 56 8C for 30
min to inactivate complement, then were serially diluted in
complete DMEM. Four hundred microliters of each
dilution was combined with 100 Al of DMEM containing
100 pfu of CVB3. These materials were incubated, with
gentle rocking, at 4 8C for 2 h. To determine if the viral
particles had been neutralized by the mouse sera, a plaque
assay was carried out as described above. Briefly, the
samples were applied to HeLa cells at approximately 70–
90% confluency, incubated for 1 h at 37 8C, then overlaid
with 1 DMEM in 0.6% agar. Approximately 48 h later,
cells were fixed and stained as indicated above. For each
serum, the neutralizing antibody titer was defined as the
dilution of antibody at which the number of plaques was
reduced by 50%. Serum IFNg was measured using the
mouse IFNg ELISA kit from eBioscience (San Diego, CA).Acknowledgments
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